Trophoblast glycoprotein antibody compositions and methods of use

Abstract

The disclosure related to antibodies that bind to 5T4 and conjugates comprising the antibodies. The disclosure also relates to methods of using the antibodies and / or antibody-conjugates and compositions comprising the antibodies and / or antibody-drug conjugates.

Description

[0001] TROPHOBLAST GLYCOPROTEIN ANTIBODY COMPOSITIONS AND METHODS OF USE

[0002] RELATED APPLICATIONS

[0003] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application number 63 / 518,504, filed August 9, 2023, and provisional application number 63 / 563,740, filed March 11, 2024, each of which is incorporated by reference herein in its entirety.

[0004] BACKGROUND

[0005] Trophoblast glycoprotein, also known as 5T4, is a transmembrane protein that is expressed on the surface of a variety of cancer cells but is absent or expressed at very low levels on normal tissues. As such, 5T4 has been identified as an attractive target for cancer therapy. Antibodies that specifically bind to 5T4 have the potential to be used for the treatment of cancer, either alone or in combination with other therapeutic agents.

[0006] SUMMARY

[0007] The present disclosure, in some aspects, relates to monoclonal antibodies that bind to 5T4 with high affinity and specificity, and methods of using these antibodies for the diagnosis and treatment of cancer. The antibodies of the present disclosure are useful for targeting and killing cancer cells that express 5T4, and can be used to deliver therapeutic agents, such as radionuclides, directly to cancer cells, while sparing normal tissues.

[0008] Some aspects of the disclosure relate to an antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of any one of SEQ ID NOs: 351-700; a complementary determining region 2 (CDR2) comprising the amino acid sequence of any one of SEQ ID NOs: 701-1050; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of any one of SEQ ID NOs: 1051-1400, wherein the antibody binds to 5T4.

[0009] In some embodiments, the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 1-350, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of any one of SEQ ID NOs: 1-350.

[0010] Some aspects relate to an antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 593; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 943; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1293. In some embodiments, this antibody binds to 5T4.

[0011] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 243, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 243.

[0012] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 421; a CDR2 comprising the amino acid sequence of SEQ ID NO: 771; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1121, wherein the antibody binds to 5T4.

[0013] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 71.

[0014] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 658; a CDR2 comprising the amino acid sequence of SEQ ID NO: 1008; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1358, wherein the antibody binds to 5T4.

[0015] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 308, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 308.

[0016] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 632; a CDR2 comprising the amino acid sequence of SEQ ID NO: 982; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1332, wherein the antibody binds to 5T4.

[0017] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 282, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 282.

[0018] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 483; a CDR2 comprising the amino acid sequence of SEQ ID NO: 833; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1183, wherein the antibody binds to 5T4.

[0019] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 133, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 133.

[0020] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 445; a CDR2 comprising the amino acid sequence of SEQ ID NO: 795; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1145, wherein the antibody binds to 5T4.

[0021] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 95, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 95.

[0022] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 408; a CDR2 comprising the amino acid sequence of SEQ ID NO: 758; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1108, wherein the antibody binds to 5T4.

[0023] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 58, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 58.

[0024] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 381; a CDR2 comprising the amino acid sequence of SEQ ID NO: 731; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1081, wherein the antibody binds to 5T4.

[0025] In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 31, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 31.

[0026] Some aspects relate to an antibody comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 623; a CDR2 comprising the amino acid sequence of SEQ ID NO: 973; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1323, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 273, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 273.

[0027] In some embodiments, the equilibrium dissociation constant (KD) of binding of the antibody to the 5T4 is in a range from 10'9M to 101M.

[0028] In some embodiments, the equilibrium dissociation constant (KD) of binding of the antibody to the 5T4 is in a range from 1 nM to 0.01 nM.

[0029] In some embodiments, the antibody selectively binds to human 5T4 relative to a nonhuman 5T4.

[0030] In some embodiments, the antibody binds to human 5T4, mouse 5T4, cynomolgus monkey 5T4, or any combination thereof.

[0031] In some embodiments, the antibody is a single chain antibody.

[0032] In some embodiments, the single chain antibody is a heavy-chain variable domain (VHH) antibody or a single-chain variable fragment (scFv) antibody.

[0033] In some embodiments, the antibody is a humanized antibody.

[0034] In some embodiments, the antibody is a chimeric antibody.

[0035] Other aspects of the disclosure relate to a cell comprising the antibody of any one of the preceding paragraphs. In some embodiments, the cell is a cancer cell.

[0036] Yet other aspects of the disclosure relate to conjugate comprising the antibody of any one of the preceding paragraphs.

[0037] In some embodiments, the conjugate further comprises a radionuclide.

[0038] In some embodiments,

[0039] Still other aspects of the disclosure relate to pharmaceutical composition comprising the antibody of any one of the preceding paragraphs and a pharmaceutically acceptable excipient.

[0040] Some aspects relate to a method comprising administering to a subject the antibody of any one of preceding paragraphs, the conjugate of any one of the preceding paragraphs, the antibody-drug conjugate of any one of preceding paragraphs, or the pharmaceutical composition of any one of preceding paragraphs.

[0041] Other aspects relate to a nucleic acid or set of nucleic acids encoding the antibody of any one of preceding paragraphs.

[0042] Yet other aspects relate to a vector or set of vectors comprising one or more nucleic acid encoding the antibody of any one of preceding paragraphs. Further aspects relate to a method of producing the antibody of any one of preceding paragraphs, the method comprising culturing the cell of any one of preceding paragraphs in cell culture and obtaining the antibody from the cell or cell culture.

[0043] BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1: RadioTLC scan of 5t4 VHHl-Fc labelled with Zr-89

[0045] Figure 2: In vivo PET imaging of H1975 tumors post 120h IV administration of Zr89 - VHHl-Fc (5t4 VHH binder) and Zr89-VHH10-Fc (negative control) in mice.

[0046] Figures 3A-3B: (Figure 3 A) Image based quantification of the accumulation of Zr89- VHH Fc’s in H1975 tumors after 120h IV administration in mice. (Figure 3B) Summary of the calculated pi’s (isoelectric point) and Biacore kinetic data of the VHH monomer clones binding to 5t4 at pH 5.5 and 7.4.

[0047] Figure 4: Relative tumor:organ uptake ratios of Zr89-VHH Fc based on the PET imaging data and % of injected dose after 120h IV injection. The dotted line represents the “non-specific uptake” levels based on the biodistribution of the non-targeting Zr89-VHH10-Fc molecule.

[0048] DETAILED DESCRIPTION

[0049] The present disclosure relates to antibodies (e.g., VHH antibodies) that specifically bind to 5T4, also known as trophoblast glycoprotein. 5T4 is a transmembrane protein that is highly expressed on the surface of a variety of cancer cells, but is absent or expressed at very low levels on normal tissues. This makes it an attractive target for cancer therapy. Antibodies that bind to 5T4 have the potential to be used for the diagnosis and treatment of cancer, either alone or in combination with other therapeutic agents, such as radionuclides. In some embodiments, the present disclosure relates to monoclonal antibodies (e.g., VHH antibodies) that bind to 5T4 with high affinity and specificity, and methods of using these antibodies for the diagnosis and treatment of cancer. The antibodies of the present disclosure are useful, for example, for targeting and killing cancer cells that express 5T4, and can be used in some embodiments to deliver therapeutic agents directly to cancer cells, while sparing normal tissues.

[0050] In some embodiments, the antibodies are VHH antibodies, also known as nanobodies. VHH antibodies are a unique type of antibody that have gained popularity in recent years due to their small size and high stability. VHH antibodies are derived from the variable region of the heavy chain-only antibodies found in the camelid family and have a molecular weight of only about 15 kDa. This small size allows them to access and bind to epitopes that are inaccessible to larger antibodies and also makes them more stable in harsh environments such as the gastrointestinal tract or extreme temperatures. VHH antibodies have shown promise as therapeutics for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. Due to their unique properties, VHH antibodies have the potential to overcome some of the limitations of traditional antibodies and may offer new opportunities for the development of therapeutics.

[0051] In some embodiments, the antibodies of the present disclosure are conjugated to a therapeutic agent, such as a radionuclide. Radionuclides are unstable atomic nuclei that emit radiation in the form of alpha, beta, or gamma particles in order to become more stable. These particles can be harnessed for a variety of purposes, including medical imaging, cancer treatment, and industrial applications. For example, alpha emitters are highly effective at killing cancer cells because they release high-energy particles that can only travel a short distance, while beta emitters are useful for imaging and therapy because they can penetrate deeper into tissue. Radionuclides used in therapeutics, for example, are often attached to targeting molecules, such as antibodies, peptides, or small molecules, in order to deliver the radiation directly to a specific cell or tissue. This targeted approach minimizes damage to healthy cells and tissues, while maximizing the radiation dose to the target. Radionuclides have been used in a range of diagnostic and therapeutic applications, including PET imaging, SPECT imaging, radioimmunotherapy, and targeted radionuclide therapy.

[0052] Antibodies Binding to 5T4

[0053] The present disclosure provides antibodies that bind to 5T4 (i.e., trophoblast glycoprotein) and are capable of targeting cells having 5T4 on their surface (e.g., cancer cells expressing 5T4). An antibody that binds to 5T4 may be referred to as an anti-5T4 antibody.

[0054] An antibody (interchangeably used in plural form) is an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term “antibody” encompasses not only intact (i.e., full-length) polyclonal or monoclonal antibodies, but also antigen-binding fragments thereof (such as Fab, Fab', F(ab')2, Fv), mutants thereof, fusion proteins comprising an antibody portion, humanized antibodies, chimeric antibodies, diabodies, nanobodies, linear antibodies, single chain antibodies (e.g., heavy-chain variable domain (VHH) antibody or a single-chain variable fragment (scFv) antibody), multispecific antibodies (e.g., bispecific antibodies) and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. An antibody includes an antibody of any class, such as IgD, IgE, IgG, IgA, or IgM (or sub-class thereof), and the antibody need not be of any particular class. Depending on the antibody amino acid sequence of the constant domain of its heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

[0055] A typical antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known in the art, for example, by the Kabat definition, the Chothia definition, the AbM definition, and / or the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). See also hgmp.mrc.ac.uk and bioinf.org.uk / abs.

[0056] In some embodiments, the anti-5T4 antibodies as described herein can bind and inhibit the activity of 5T4 by at least 50% (e.g., 60%, 70%, 80%, 90%, 95% or greater). The apparent inhibition constant (Kiappor Ki,app), which provides a measure of inhibitor potency, is related to the concentration of inhibitor required to reduce enzyme activity and is not dependent on enzyme concentrations. The inhibitory activity of an anti-5T4 antibody described herein can be determined by routine methods known in the art. The antibodies described herein can be murine, rat, human, camelid (including from camels, alpacas, and llamas), or any other origin (including chimeric or humanized antibodies). Such antibodies are non-naturally occurring, i.e., would not be produced in an animal without human act (e.g., immunizing such an animal with a desired antigen or fragment thereof).

[0057] Any of the antibodies described herein can be either monoclonal or polyclonal. A “monoclonal antibody” refers to a homogenous antibody population and a “polyclonal antibody” refers to a heterogeneous antibody population. These two terms do not limit the source of an antibody or the manner in which it is made.

[0058] In one example, an antibody used in the methods described herein is a humanized antibody. Humanized antibodies refer to forms of non-human (e.g., murine) antibodies that are specific chimeric immunoglobulins, immunoglobulin chains, or antigen-binding fragments thereof that contain minimal sequence derived from non-human immunoglobulin. In some embodiments, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences but are included to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Antibodies may have Fc regions modified as described in WO 99 / 58572.

[0059] In some embodiments, humanized antibodies are a heavy-chain variable domain (VHH) antibodies in which camelid- specific amino acids in the framework region(s) have been replaced with corresponding human- specific amino acids. A humanized VHH antibody has been changed such that immunogenicity upon administration of the VHH in human patients is minor or nonexistent. Humanizing a VHH antibody may comprise a step of replacing one or more of the Camelidae amino acids by their human counterpart as found in the human consensus sequence, without that VHH losing its typical character (e.g., the humanization does not significantly affect the antigen binding capacity of the resulting VHH). In some embodiments, humanization of single domain antibodies (e.g., VHH antibodies) requires the introduction and mutagenesis of a limited number of amino acids in a single VHH chain. This is in contrast to humanization of scFv, Fab, (Fab)2 and IgG, which requires the introduction of amino acid changes in two chains, the light and the heavy chain and the preservation of the assembly of both chains.

[0060] Other forms of humanized antibodies have one or more CDRs (one, two, three, four, five, and / or six), which are altered with respect to the original antibody, which are also termed one or more CDRs “derived from” one or more CDRs from the original antibody. Humanized antibodies may also involve affinity maturation.

[0061] In another example, an antibody described herein can be a chimeric antibody, which can include a heavy constant region and a light constant region from a human antibody. Chimeric antibodies refer to antibodies having a variable region or part of variable region from a first species and a constant region from a second species. Typically, in these chimeric antibodies, the variable region of both light and heavy chains mimics the variable regions of antibodies derived from one species of mammals (e.g., a non-human mammal such as mouse, rabbit, and rat), while the constant portions are homologous to the sequences in antibodies derived from another mammal such as human. In some embodiments, amino acid modifications can be made in the variable region and / or the constant region.

[0062] In some embodiments, the anti-5T4 antibodies described herein specifically bind to the corresponding target antigen or an epitope thereof. A molecule is said to exhibit “specific binding” if it reacts more frequently, more rapidly, with greater duration and / or with greater affinity with a particular target antigen than it does with alternative targets. An antibody “specifically binds” to a target antigen or epitope if it binds with greater affinity, avidity, more readily, and / or with greater duration than it binds to other substances. An antibody that specifically (or preferentially) binds to 5T4 or an antigenic epitope therein is an antibody that binds this target antigen with greater affinity, avidity, more readily, and / or with greater duration than it binds to other antigens or other epitopes in the same antigen. It is also understood with this definition that, for example, an antibody that specifically binds to a first target antigen may or may not specifically or preferentially bind to a second target antigen. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding. In some examples, an antibody that “specifically binds” to a target antigen or an epitope thereof may not bind to other antigens or other epitopes in the same antigen. In some embodiments, the anti-5T4 antibodies described herein specifically binds human 5T4. In some examples, its binding activity to a non-human 5T4 antigen is not detectable in a conventional assay or is very low such that it would have no significant biological significance as known to those skilled in the art. In other examples, the anti-5T4 antibodies described herein may crossreact with 5T4 from different species, for example, between human 5T4 and a non-human 5T4 (e.g., 5T4 from an experimental animal such as a non-human primate, mouse, or rat).

[0063] In some embodiments, an anti-5T4 antibody may specifically bind to any extracellular epitope of 5T4 or an epitope that becomes exposed to an antibody. In some embodiments, an anti-5T4 antibody binds to an amino acid segment of a human or non-human primate 5T4. In some embodiments, an anti-5T4 antibody specifically binds to its target with a binding affinity (KD) of about 0.01 nM to about 1 nM. In some embodiments, an anti-5T4 antibody specifically binds to its target with a KD of about 0.001 nM to about 10 nM. In some embodiments, an anti- 5T4 antibody specifically binds to its target with a KD of about 10'6M, 10'7M, 10'8M, 10'9M, 100M, 101M, 102M, 1043M. In some embodiments, an anti-5T4 antibody specifically binds to its target with a KD of about 10'9M to 1041M.

[0064] An example human 5T4 amino acid sequence, corresponding to NCBI sequence NP_001159864.1 (Trophoblast Glycoprotein Precursor, Homo sapiens) is as follows: MPGGCSRGPA AGDGRLRLAR LALVLLGWVS SSSPTSSASS FSSSAPFLAS AVSAQPPLPD QCPALCECSE AARTVKCVNR NLTEVPTDLP AYVRNLFLTG NQLAVLPAGA FARRPPLAEL AALNLSGSRL DEVRAGAFEH LPSLRQLDLS HNPLADLSPF AFSGSNASVS APSPLVELIL NHIVPPEDER QNRSFEGMW AALLAGRALQ GLRRLELASN HFLYLPRDVL AQLPSLRHLD LSNNSLVSLT YVSFRNLTHL ESLHLEDNAL KVLHNGTLAE LQGLPHIRVF LDNNPWVCDC HMADMVTWLK ETEWQGKDR LTCAYPEKMR NRVLLELNSA DLDCDP ILPP SLQTSYVFLG IVLALIGAIF LLVLYLNRKG IKKWMHNIRD ACRDHMEGYH YRYEINADPR LTNLSSNSDV (SEQ ID NO: 1401).

[0065] In some embodiments, an anti-5T4 antibody as described herein has a suitable binding affinity for the target antigen (e.g., human 5T4) or antigenic epitopes thereof. As used herein, “binding affinity” refers to the apparent association constant (KA). The KA is the reciprocal of the dissociation constant (KD). An increased binding affinity corresponds to a decreased KD. Higher affinity binding of an antibody for a first antigen relative to a second antigen can be indicated by a higher KA (or a smaller numerical value KD) for binding the first antigen than the KA (or numerical value KD) for binding the second antigen. In such cases, an antibody has specificity for the first antigen e.g., a first protein in a first conformation or mimic thereof) relative to the second antigen (e.g., the same first protein in a second conformation or mimic thereof; or a second protein). In some embodiments, the anti-5T4 antibodies described herein have a higher binding affinity (a higher KA or smaller KD) to human 5T4 as compared to the binding affinity to 5T4 of a different species. Differences in binding affinity (e.g., for specificity or other comparisons) can be at least 1.5, 2, 3, 4, 5, 10, 15, 20, 37.5, 50, 70, 80, 91, 100, 500, 1000, 10,000 or 105fold. In some embodiments, any of the anti-5T4 antibodies may be further affinity matured to increase the binding affinity of the antibody to the target antigen or antigenic epitope thereof.

[0066] Binding affinity (or binding specificity) can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g., using a fluorescence assay). Exemplary conditions for evaluating binding affinity are in HBS-P buffer (10 mM HEPES pH7.4, 150 mM NaCl, 0.005% (v / v) Surfactant P20). These techniques can be used to measure the concentration of bound binding protein as a function of target protein concentration. The concentration of bound binding protein ([Bound]) is generally related to the concentration of free target protein ([Free]) by the following equation:

[0067] [Bound] = [Free] / (KD+[Free])

[0068] It is not always necessary to make an exact determination of KA, though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined using a method such as ELISA or FACS analysis, is proportional to KA, and thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher, to obtain a qualitative measurement of affinity, or to obtain an inference of affinity, e.g., by activity in a functional assay, e.g., an in vitro or in vivo assay.

[0069] In some embodiments, the anti-5T4 antibodies described herein bind to the same epitope in a 5T4 antigen (e.g., human 5T4) as a reference antibody known in the art. In some embodiments, the reference antibody is PF-06281192 (huAlmAb). An antibody that binds the same epitope as a reference antibody described herein may bind to the same epitope or a substantially overlapping epitope (e.g., containing less than 3 non-overlapping amino acid residue, less than 2 non-overlapping amino acid residues, or only 1 non-overlapping amino acid residue) as the reference antibody. Whether two antibodies compete against each other from binding to the cognate antigen can be determined by a competition assay, which is well known in the art. Such antibodies can be identified as known to those skilled in the art, e.g., those having substantially similar structural features (e.g., complementary determining regions), and / or those identified by assays known in the art. For example, competition assays can be performed using one of the reference antibodies to determine whether a candidate antibody binds to the same epitope as the reference antibody or competes against its binding to the 5T4 antigen.

[0070] The anti-5T4 antibodies described herein may comprise a complementary determining region 1 (CDR1), a complementary determining region 2 (CDR2), and a complementary determining region 3 (CDR3).

[0071] In some embodiments, an anti-5T4 antibody is a single-chain antibody (e.g., heavy-chain variable domain (VHH) antibody or a single-chain variable fragment (scFv) antibody). In some embodiments, an anti-5T4 antibody is a heavy-chain variable domain (VHH) antibody.

[0072] In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0073] 1051. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0074] 1052. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0075] 1053. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0076] 1054. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0077] 1055. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0078] 1056. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0079] 1057. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0080] 1058. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0081] 1059. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0082] 1060. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0083] 1061. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0084] 1062. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0085] 1063. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0086] 1064. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0087] 1065. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0088] 1066. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0089] 1067. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0090] 1068. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0091] 1069. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0092] 1070. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0093] 1071. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0094] 1072. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1073. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0095] 1074. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0096] 1075. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0097] 1076. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0098] 1077. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0099] 1078. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0100] 1079. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0101] 1080. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0102] 1081. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0103] 1082. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0104] 1083. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0105] 1084. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0106] 1085. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0107] 1086. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0108] 1087. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0109] 1088. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0110] 1089. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0111] 1090. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0112] 1091. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0113] 1092. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0114] 1093. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0115] 1094. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0116] 1095. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0117] 1096. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0118] 1097. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0119] 1098. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0120] 1099. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0121] 1100. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0122] 1101. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0123] 1102. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0124] 1103. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0125] 1104. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0126] 1105. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1106. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0127] 1107. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0128] 1108. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0129] 1109. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0130] 1110. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0131] 1111. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0132] 1112. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0133] 1113. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0134] 1114. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0135] 1115. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0136] 1116. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0137] 1117. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0138] 1118. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0139] 1119. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0140] 1120. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0141] 1121. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0142] 1122. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0143] 1123. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0144] 1124. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0145] 1125. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0146] 1126. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0147] 1127. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0148] 1128. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0149] 1129. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0150] 1130. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0151] 1131. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0152] 1132. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0153] 1133. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0154] 1134. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0155] 1135. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0156] 1136. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0157] 1137. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0158] 1138. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1139. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0159] 1140. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0160] 1141. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0161] 1142. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0162] 1143. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0163] 1144. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0164] 1145. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0165] 1146. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0166] 1147. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0167] 1148. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0168] 1149. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0169] 1150. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0170] 1151. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0171] 1152. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0172] 1153. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0173] 1154. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0174] 1155. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0175] 1156. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0176] 1157. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0177] 1158. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0178] 1159. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0179] 1160. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0180] 1161. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0181] 1162. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0182] 1163. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0183] 1164. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0184] 1165. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0185] 1166. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0186] 1167. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0187] 1168. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0188] 1169. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0189] 1170. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0190] 1171. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1172. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0191] 1173. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0192] 1174. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0193] 1175. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0194] 1176. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0195] 1177. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0196] 1178. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0197] 1179. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0198] 1180. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0199] 1181. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0200] 1182. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0201] 1183. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0202] 1184. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0203] 1185. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0204] 1186. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0205] 1187. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0206] 1188. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0207] 1189. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0208] 1190. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0209] 1191. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0210] 1192. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0211] 1193. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0212] 1194. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0213] 1195. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0214] 1196. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0215] 1197. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0216] 1198. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0217] 1199. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0218] 1200. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0219] 1201. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0220] 1202. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0221] 1203. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0222] 1204. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1205. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0223] 1206. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0224] 1207. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0225] 1208. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0226] 1209. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0227] 1210. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0228] 1211. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0229] 1212. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0230] 1213. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0231] 1214. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0232] 1215. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0233] 1216. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0234] 1217. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0235] 1218. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0236] 1219. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0237] 1220. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0238] 1221. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0239] 1222. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0240] 1223. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0241] 1224. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0242] 1225. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0243] 1226. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0244] 1227. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0245] 1228. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0246] 1229. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0247] 1230. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0248] 1231. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0249] 1232. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0250] 1233. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0251] 1234. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0252] 1235. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0253] 1236. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0254] 1237. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1238. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0255] 1239. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0256] 1240. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0257] 1241. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0258] 1242. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0259] 1243. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0260] 1244. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0261] 1245. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0262] 1246. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0263] 1247. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0264] 1248. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0265] 1249. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0266] 1250. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0267] 1251. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0268] 1252. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0269] 1253. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0270] 1254. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0271] 1255. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0272] 1256. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0273] 1257. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0274] 1258. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0275] 1259. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0276] 1260. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0277] 1261. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0278] 1262. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0279] 1263. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0280] 1264. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0281] 1265. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0282] 1266. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0283] 1267. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0284] 1268. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0285] 1269. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0286] 1270. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1271. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0287] 1272. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0288] 1273. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0289] 1274. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0290] 1275. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0291] 1276. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0292] 1277. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0293] 1278. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0294] 1279. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0295] 1280. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0296] 1281. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0297] 1282. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0298] 1283. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0299] 1284. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0300] 1285. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0301] 1286. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0302] 1287. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0303] 1288. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0304] 1289. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0305] 1290. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0306] 1291. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0307] 1292. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0308] 1293. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0309] 1294. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0310] 1295. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0311] 1296. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0312] 1297. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0313] 1298. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0314] 1299. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0315] 1300. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0316] 1301. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0317] 1302. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0318] 1303. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1304. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0319] 1305. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0320] 1306. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0321] 1307. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0322] 1308. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0323] 1309. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0324] 1310. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0325] 1311. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0326] 1312. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0327] 1313. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0328] 1314. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0329] 1315. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0330] 1316. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0331] 1317. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0332] 1318. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0333] 1319. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0334] 1320. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0335] 1321. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0336] 1322. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0337] 1323. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0338] 1324. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0339] 1325. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0340] 1326. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0341] 1327. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0342] 1328. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0343] 1329. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0344] 1330. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0345] 1331. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0346] 1332. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0347] 1333. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0348] 1334. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0349] 1335. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0350] 1336. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1337. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0351] 1338. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0352] 1339. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0353] 1340. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0354] 1341. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0355] 1342. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0356] 1343. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0357] 1344. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0358] 1345. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0359] 1346. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0360] 1347. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0361] 1348. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0362] 1349. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0363] 1350. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0364] 1351. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0365] 1352. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0366] 1353. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0367] 1354. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0368] 1355. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0369] 1356. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0370] 1357. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0371] 1358. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0372] 1359. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0373] 1360. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0374] 1361. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0375] 1362. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0376] 1363. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0377] 1364. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0378] 1365. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0379] 1366. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0380] 1367. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0381] 1368. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0382] 1369. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1370. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0383] 1371. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0384] 1372. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0385] 1373. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0386] 1374. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0387] 1375. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0388] 1376. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0389] 1377. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0390] 1378. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0391] 1379. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0392] 1380. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0393] 1381. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0394] 1382. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0395] 1383. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0396] 1384. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0397] 1385. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0398] 1386. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0399] 1387. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0400] 1388. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0401] 1389. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0402] 1390. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0403] 1391. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0404] 1392. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0405] 1393. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0406] 1394. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0407] 1395. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0408] 1396. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0409] 1397. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0410] 1398. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0411] 1399. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO:

[0412] 1400.

[0413] In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 351, the amino acid sequence of SEQ ID NO: 701, and / or the amino acid sequence of SEQ ID NO: 1051. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 352, the amino acid sequence of SEQ ID NO: 702, and / or the amino acid sequence of SEQ ID NO: 1052. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 353, the amino acid sequence of SEQ ID NO: 703, and / or the amino acid sequence of SEQ ID NO: 1053. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 354, the amino acid sequence of SEQ ID NO: 704, and / or the amino acid sequence of SEQ ID NO: 1054. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 355, the amino acid sequence of SEQ ID NO: 705, and / or the amino acid sequence of SEQ ID NO: 1055. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 356, the amino acid sequence of SEQ ID NO: 706, and / or the amino acid sequence of SEQ ID NO: 1056. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 357, the amino acid sequence of SEQ ID NO: 707, and / or the amino acid sequence of SEQ ID NO: 1057. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 358, the amino acid sequence of SEQ ID NO: 708, and / or the amino acid sequence of SEQ ID NO: 1058. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 359, the amino acid sequence of SEQ ID NO: 709, and / or the amino acid sequence of SEQ ID NO: 1059. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 360, the amino acid sequence of SEQ ID NO: 710, and / or the amino acid sequence of SEQ ID NO: 1060. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 361, the amino acid sequence of SEQ ID NO: 711, and / or the amino acid sequence of SEQ ID NO: 1061. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 362, the amino acid sequence of SEQ ID NO: 712, and / or the amino acid sequence of SEQ ID NO: 1062. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 363, the amino acid sequence of SEQ ID NO: 713, and / or the amino acid sequence of SEQ ID NO: 1063. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 364, the amino acid sequence of SEQ ID NO: 714, and / or the amino acid sequence of SEQ ID NO: 1064. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 365, the amino acid sequence of SEQ ID NO: 715, and / or the amino acid sequence of SEQ ID NO: 1065. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 366, the amino acid sequence of SEQ ID NO: 716, and / or the amino acid sequence of SEQ ID NO: 1066. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 367, the amino acid sequence of SEQ ID NO: 717, and / or the amino acid sequence of SEQ ID NO: 1067. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 368, the amino acid sequence of SEQ ID NO: 718, and / or the amino acid sequence of SEQ ID NO: 1068. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 369, the amino acid sequence of SEQ ID NO: 719, and / or the amino acid sequence of SEQ ID NO: 1069. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 370, the amino acid sequence of SEQ ID NO: 720, and / or the amino acid sequence of SEQ ID NO: 1070. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 371, the amino acid sequence of SEQ ID NO: 721, and / or the amino acid sequence of SEQ ID NO: 1071. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 372, the amino acid sequence of SEQ ID NO: 722, and / or the amino acid sequence of SEQ ID NO: 1072. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 373, the amino acid sequence of SEQ ID NO: 723, and / or the amino acid sequence of SEQ ID NO: 1073. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 374, the amino acid sequence of SEQ ID NO: 724, and / or the amino acid sequence of SEQ ID NO: 1074. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 375, the amino acid sequence of SEQ ID NO: 725, and / or the amino acid sequence of SEQ ID NO: 1075. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 376, the amino acid sequence of SEQ ID NO: 726, and / or the amino acid sequence of SEQ ID NO: 1076. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 377, the amino acid sequence of SEQ ID NO: 727, and / or the amino acid sequence of SEQ ID NO: 1077. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 378, the amino acid sequence of SEQ ID NO: 728, and / or the amino acid sequence of SEQ ID NO: 1078. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 379, the amino acid sequence of SEQ ID NO: 729, and / or the amino acid sequence of SEQ ID NO: 1079. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 380, the amino acid sequence of SEQ ID NO: 730, and / or the amino acid sequence of SEQ ID NO: 1080. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 381, the amino acid sequence of SEQ ID NO: 731, and / or the amino acid sequence of SEQ ID NO: 1081. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 382, the amino acid sequence of SEQ ID NO: 732, and / or the amino acid sequence of SEQ ID NO: 1082. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 383, the amino acid sequence of SEQ ID NO: 733, and / or the amino acid sequence of SEQ ID NO: 1083. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 384, the amino acid sequence of SEQ ID NO: 734, and / or the amino acid sequence of SEQ ID NO: 1084. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 385, the amino acid sequence of SEQ ID NO: 735, and / or the amino acid sequence of SEQ ID NO: 1085. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 386, the amino acid sequence of SEQ ID NO: 736, and / or the amino acid sequence of SEQ ID NO: 1086. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 387, the amino acid sequence of SEQ ID NO: 737, and / or the amino acid sequence of SEQ ID NO: 1087. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 388, the amino acid sequence of SEQ ID NO: 738, and / or the amino acid sequence of SEQ ID NO: 1088. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 389, the amino acid sequence of SEQ ID NO: 739, and / or the amino acid sequence of SEQ ID NO: 1089. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 390, the amino acid sequence of SEQ ID NO: 740, and / or the amino acid sequence of SEQ ID NO: 1090. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 391, the amino acid sequence of SEQ ID NO: 741, and / or the amino acid sequence of SEQ ID NO: 1091. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 392, the amino acid sequence of SEQ ID NO: 742, and / or the amino acid sequence of SEQ ID NO: 1092. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 393, the amino acid sequence of SEQ ID NO: 743, and / or the amino acid sequence of SEQ ID NO: 1093. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 394, the amino acid sequence of SEQ ID NO: 744, and / or the amino acid sequence of SEQ ID NO: 1094. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 395, the amino acid sequence of SEQ ID NO: 745, and / or the amino acid sequence of SEQ ID NO: 1095. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 396, the amino acid sequence of SEQ ID NO: 746, and / or the amino acid sequence of SEQ ID NO: 1096. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 397, the amino acid sequence of SEQ ID NO: 747, and / or the amino acid sequence of SEQ ID NO: 1097. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 398, the amino acid sequence of SEQ ID NO: 748, and / or the amino acid sequence of SEQ ID NO: 1098. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 399, the amino acid sequence of SEQ ID NO: 749, and / or the amino acid sequence of SEQ ID NO: 1099. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 400, the amino acid sequence of SEQ ID NO: 750, and / or the amino acid sequence of SEQ ID NO: 1100. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 401, the amino acid sequence of SEQ ID NO: 751, and / or the amino acid sequence of SEQ ID NO: 1101. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 402, the amino acid sequence of SEQ ID NO: 752, and / or the amino acid sequence of SEQ ID NO: 1102. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 403, the amino acid sequence of SEQ ID NO: 753, and / or the amino acid sequence of SEQ ID NO: 1103. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 404, the amino acid sequence of SEQ ID NO: 754, and / or the amino acid sequence of SEQ ID NO: 1104. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 405, the amino acid sequence of SEQ ID NO: 755, and / or the amino acid sequence of SEQ ID NO: 1105. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 406, the amino acid sequence of SEQ ID NO: 756, and / or the amino acid sequence of SEQ ID NO: 1106. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 407, the amino acid sequence of SEQ ID NO: 757, and / or the amino acid sequence of SEQ ID NO: 1107. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 408, the amino acid sequence of SEQ ID NO: 758, and / or the amino acid sequence of SEQ ID NO: 1108. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 409, the amino acid sequence of SEQ ID NO: 759, and / or the amino acid sequence of SEQ ID NO: 1109. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 410, the amino acid sequence of SEQ ID NO: 760, and / or the amino acid sequence of SEQ ID NO: 1110. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 411, the amino acid sequence of SEQ ID NO: 761, and / or the amino acid sequence of SEQ ID NO: 1111. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 412, the amino acid sequence of SEQ ID NO: 762, and / or the amino acid sequence of SEQ ID NO: 1112. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 413, the amino acid sequence of SEQ ID NO: 763, and / or the amino acid sequence of SEQ ID NO: 1113. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 414, the amino acid sequence of SEQ ID NO: 764, and / or the amino acid sequence of SEQ ID NO: 1114. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 415, the amino acid sequence of SEQ ID NO: 765, and / or the amino acid sequence of SEQ ID NO: 1115. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 416, the amino acid sequence of SEQ ID NO: 766, and / or the amino acid sequence of SEQ ID NO: 1116. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 417, the amino acid sequence of SEQ ID NO: 767, and / or the amino acid sequence of SEQ ID NO: 1117. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 418, the amino acid sequence of SEQ ID NO: 768, and / or the amino acid sequence of SEQ ID NO: 1118. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 419, the amino acid sequence of SEQ ID NO: 769, and / or the amino acid sequence of SEQ ID NO: 1119. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 420, the amino acid sequence of SEQ ID NO: 770, and / or the amino acid sequence of SEQ ID NO: 1120. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 421, the amino acid sequence of SEQ ID NO: 771, and / or the amino acid sequence of SEQ ID NO: 1121. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 422, the amino acid sequence of SEQ ID NO: 772, and / or the amino acid sequence of SEQ ID NO: 1122. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 423, the amino acid sequence of SEQ ID NO: 773, and / or the amino acid sequence of SEQ ID NO: 1123. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 424, the amino acid sequence of SEQ ID NO: 774, and / or the amino acid sequence of SEQ ID NO: 1124. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 425, the amino acid sequence of SEQ ID NO: 775, and / or the amino acid sequence of SEQ ID NO: 1125. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 426, the amino acid sequence of SEQ ID NO: 776, and / or the amino acid sequence of SEQ ID NO: 1126. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 427, the amino acid sequence of SEQ ID NO: 777, and / or the amino acid sequence of SEQ ID NO: 1127. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 428, the amino acid sequence of SEQ ID NO: 778, and / or the amino acid sequence of SEQ ID NO: 1128. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 429, the amino acid sequence of SEQ ID NO: 779, and / or the amino acid sequence of SEQ ID NO: 1129. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 430, the amino acid sequence of SEQ ID NO: 780, and / or the amino acid sequence of SEQ ID NO: 1130. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 431, the amino acid sequence of SEQ ID NO: 781, and / or the amino acid sequence of SEQ ID NO: 1131. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 432, the amino acid sequence of SEQ ID NO: 782, and / or the amino acid sequence of SEQ ID NO: 1132. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 433, the amino acid sequence of SEQ ID NO: 783, and / or the amino acid sequence of SEQ ID NO: 1133. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 434, the amino acid sequence of SEQ ID NO: 784, and / or the amino acid sequence of SEQ ID NO: 1134. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 435, the amino acid sequence of SEQ ID NO: 785, and / or the amino acid sequence of SEQ ID NO: 1135. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 436, the amino acid sequence of SEQ ID NO: 786, and / or the amino acid sequence of SEQ ID NO: 1136. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 437, the amino acid sequence of SEQ ID NO: 787, and / or the amino acid sequence of SEQ ID NO: 1137. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 438, the amino acid sequence of SEQ ID NO: 788, and / or the amino acid sequence of SEQ ID NO: 1138. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 439, the amino acid sequence of SEQ ID NO: 789, and / or the amino acid sequence of SEQ ID NO: 1139. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 440, the amino acid sequence of SEQ ID NO: 790, and / or the amino acid sequence of SEQ ID NO: 1140. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 441, the amino acid sequence of SEQ ID NO: 791, and / or the amino acid sequence of SEQ ID NO: 1141. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 442, the amino acid sequence of SEQ ID NO: 792, and / or the amino acid sequence of SEQ ID NO: 1142. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 443, the amino acid sequence of SEQ ID NO: 793, and / or the amino acid sequence of SEQ ID NO: 1143. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 444, the amino acid sequence of SEQ ID NO: 794, and / or the amino acid sequence of SEQ ID NO: 1144. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 445, the amino acid sequence of SEQ ID NO: 795, and / or the amino acid sequence of SEQ ID NO: 1145. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 446, the amino acid sequence of SEQ ID NO: 796, and / or the amino acid sequence of SEQ ID NO: 1146. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 447, the amino acid sequence of SEQ ID NO: 797, and / or the amino acid sequence of SEQ ID NO: 1147. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 448, the amino acid sequence of SEQ ID NO: 798, and / or the amino acid sequence of SEQ ID NO: 1148. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 449, the amino acid sequence of SEQ ID NO: 799, and / or the amino acid sequence of SEQ ID NO: 1149. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 450, the amino acid sequence of SEQ ID NO: 800, and / or the amino acid sequence of SEQ ID NO: 1150. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 451, the amino acid sequence of SEQ ID NO: 801, and / or the amino acid sequence of SEQ ID NO: 1151. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 452, the amino acid sequence of SEQ ID NO: 802, and / or the amino acid sequence of SEQ ID NO: 1152. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 453, the amino acid sequence of SEQ ID NO: 803, and / or the amino acid sequence of SEQ ID NO: 1153. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 454, the amino acid sequence of SEQ ID NO: 804, and / or the amino acid sequence of SEQ ID NO: 1154. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 455, the amino acid sequence of SEQ ID NO: 805, and / or the amino acid sequence of SEQ ID NO: 1155. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 456, the amino acid sequence of SEQ ID NO: 806, and / or the amino acid sequence of SEQ ID NO: 1156. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 457, the amino acid sequence of SEQ ID NO: 807, and / or the amino acid sequence of SEQ ID NO: 1157. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 458, the amino acid sequence of SEQ ID NO: 808, and / or the amino acid sequence of SEQ ID NO: 1158. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 459, the amino acid sequence of SEQ ID NO: 809, and / or the amino acid sequence of SEQ ID NO: 1159. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 460, the amino acid sequence of SEQ ID NO: 810, and / or the amino acid sequence of SEQ ID NO: 1160. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 461, the amino acid sequence of SEQ ID NO: 811, and / or the amino acid sequence of SEQ ID NO: 1161. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 462, the amino acid sequence of SEQ ID NO: 812, and / or the amino acid sequence of SEQ ID NO: 1162. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 463, the amino acid sequence of SEQ ID NO: 813, and / or the amino acid sequence of SEQ ID NO: 1163. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 464, the amino acid sequence of SEQ ID NO: 814, and / or the amino acid sequence of SEQ ID NO: 1164. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 465, the amino acid sequence of SEQ ID NO: 815, and / or the amino acid sequence of SEQ ID NO: 1165. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 466, the amino acid sequence of SEQ ID NO: 816, and / or the amino acid sequence of SEQ ID NO: 1166. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 467, the amino acid sequence of SEQ ID NO: 817, and / or the amino acid sequence of SEQ ID NO: 1167. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 468, the amino acid sequence of SEQ ID NO: 818, and / or the amino acid sequence of SEQ ID NO: 1168. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 469, the amino acid sequence of SEQ ID NO: 819, and / or the amino acid sequence of SEQ ID NO: 1169. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 470, the amino acid sequence of SEQ ID NO: 820, and / or the amino acid sequence of SEQ ID NO: 1170. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 471, the amino acid sequence of SEQ ID NO: 821, and / or the amino acid sequence of SEQ ID NO: 1171. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 472, the amino acid sequence of SEQ ID NO: 822, and / or the amino acid sequence of SEQ ID NO: 1172. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 473, the amino acid sequence of SEQ ID NO: 823, and / or the amino acid sequence of SEQ ID NO: 1173. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 474, the amino acid sequence of SEQ ID NO: 824, and / or the amino acid sequence of SEQ ID NO: 1174. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 475, the amino acid sequence of SEQ ID NO: 825, and / or the amino acid sequence of SEQ ID NO: 1175. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 476, the amino acid sequence of SEQ ID NO: 826, and / or the amino acid sequence of SEQ ID NO: 1176. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 477, the amino acid sequence of SEQ ID NO: 827, and / or the amino acid sequence of SEQ ID NO: 1177. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 478, the amino acid sequence of SEQ ID NO: 828, and / or the amino acid sequence of SEQ ID NO: 1178. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 479, the amino acid sequence of SEQ ID NO: 829, and / or the amino acid sequence of SEQ ID NO: 1179. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 480, the amino acid sequence of SEQ ID NO: 830, and / or the amino acid sequence of SEQ ID NO: 1180. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 481, the amino acid sequence of SEQ ID NO: 831, and / or the amino acid sequence of SEQ ID NO: 1181. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 482, the amino acid sequence of SEQ ID NO: 832, and / or the amino acid sequence of SEQ ID NO: 1182. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 483, the amino acid sequence of SEQ ID NO: 833, and / or the amino acid sequence of SEQ ID NO: 1183. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 484, the amino acid sequence of SEQ ID NO: 834, and / or the amino acid sequence of SEQ ID NO: 1184. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 485, the amino acid sequence of SEQ ID NO: 835, and / or the amino acid sequence of SEQ ID NO: 1185. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 486, the amino acid sequence of SEQ ID NO: 836, and / or the amino acid sequence of SEQ ID NO: 1186. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 487, the amino acid sequence of SEQ ID NO: 837, and / or the amino acid sequence of SEQ ID NO: 1187. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 488, the amino acid sequence of SEQ ID NO: 838, and / or the amino acid sequence of SEQ ID NO: 1188. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 489, the amino acid sequence of SEQ ID NO: 839, and / or the amino acid sequence of SEQ ID NO: 1189. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 490, the amino acid sequence of SEQ ID NO: 840, and / or the amino acid sequence of SEQ ID NO: 1190. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 491, the amino acid sequence of SEQ ID NO: 841, and / or the amino acid sequence of SEQ ID NO: 1191. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 492, the amino acid sequence of SEQ ID NO: 842, and / or the amino acid sequence of SEQ ID NO: 1192. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 493, the amino acid sequence of SEQ ID NO: 843, and / or the amino acid sequence of SEQ ID NO: 1193. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 494, the amino acid sequence of SEQ ID NO: 844, and / or the amino acid sequence of SEQ ID NO: 1194. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 495, the amino acid sequence of SEQ ID NO: 845, and / or the amino acid sequence of SEQ ID NO: 1195. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 496, the amino acid sequence of SEQ ID NO: 846, and / or the amino acid sequence of SEQ ID NO: 1196. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 497, the amino acid sequence of SEQ ID NO: 847, and / or the amino acid sequence of SEQ ID NO: 1197. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 498, the amino acid sequence of SEQ ID NO: 848, and / or the amino acid sequence of SEQ ID NO: 1198. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 499, the amino acid sequence of SEQ ID NO: 849, and / or the amino acid sequence of SEQ ID NO: 1199. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 500, the amino acid sequence of SEQ ID NO: 850, and / or the amino acid sequence of SEQ ID NO: 1200. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 501, the amino acid sequence of SEQ ID NO: 851, and / or the amino acid sequence of SEQ ID NO: 1201. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 502, the amino acid sequence of SEQ ID NO: 852, and / or the amino acid sequence of SEQ ID NO: 1202. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 503, the amino acid sequence of SEQ ID NO: 853, and / or the amino acid sequence of SEQ ID NO: 1203. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 504, the amino acid sequence of SEQ ID NO: 854, and / or the amino acid sequence of SEQ ID NO: 1204. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 505, the amino acid sequence of SEQ ID NO: 855, and / or the amino acid sequence of SEQ ID NO: 1205. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 506, the amino acid sequence of SEQ ID NO: 856, and / or the amino acid sequence of SEQ ID NO: 1206. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 507, the amino acid sequence of SEQ ID NO: 857, and / or the amino acid sequence of SEQ ID NO: 1207. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 508, the amino acid sequence of SEQ ID NO: 858, and / or the amino acid sequence of SEQ ID NO: 1208. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 509, the amino acid sequence of SEQ ID NO: 859, and / or the amino acid sequence of SEQ ID NO: 1209. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 510, the amino acid sequence of SEQ ID NO: 860, and / or the amino acid sequence of SEQ ID NO: 1210. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 511, the amino acid sequence of SEQ ID NO: 861, and / or the amino acid sequence of SEQ ID NO: 1211. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 512, the amino acid sequence of SEQ ID NO: 862, and / or the amino acid sequence of SEQ ID NO: 1212. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 513, the amino acid sequence of SEQ ID NO: 863, and / or the amino acid sequence of SEQ ID NO: 1213. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 514, the amino acid sequence of SEQ ID NO: 864, and / or the amino acid sequence of SEQ ID NO: 1214. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 515, the amino acid sequence of SEQ ID NO: 865, and / or the amino acid sequence of SEQ ID NO: 1215. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 516, the amino acid sequence of SEQ ID NO: 866, and / or the amino acid sequence of SEQ ID NO: 1216. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 517, the amino acid sequence of SEQ ID NO: 867, and / or the amino acid sequence of SEQ ID NO: 1217. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 518, the amino acid sequence of SEQ ID NO: 868, and / or the amino acid sequence of SEQ ID NO: 1218. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 519, the amino acid sequence of SEQ ID NO: 869, and / or the amino acid sequence of SEQ ID NO: 1219. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 520, the amino acid sequence of SEQ ID NO: 870, and / or the amino acid sequence of SEQ ID NO: 1220. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 521, the amino acid sequence of SEQ ID NO: 871, and / or the amino acid sequence of SEQ ID NO: 1221. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 522, the amino acid sequence of SEQ ID NO: 872, and / or the amino acid sequence of SEQ ID NO: 1222. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 523, the amino acid sequence of SEQ ID NO: 873, and / or the amino acid sequence of SEQ ID NO: 1223. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 524, the amino acid sequence of SEQ ID NO: 874, and / or the amino acid sequence of SEQ ID NO: 1224. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 525, the amino acid sequence of SEQ ID NO: 875, and / or the amino acid sequence of SEQ ID NO: 1225. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 526, the amino acid sequence of SEQ ID NO: 876, and / or the amino acid sequence of SEQ ID NO: 1226. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 527, the amino acid sequence of SEQ ID NO: 877, and / or the amino acid sequence of SEQ ID NO: 1227. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 528, the amino acid sequence of SEQ ID NO: 878, and / or the amino acid sequence of SEQ ID NO: 1228. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 529, the amino acid sequence of SEQ ID NO: 879, and / or the amino acid sequence of SEQ ID NO: 1229. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 530, the amino acid sequence of SEQ ID NO: 880, and / or the amino acid sequence of SEQ ID NO: 1230. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 531, the amino acid sequence of SEQ ID NO: 881, and / or the amino acid sequence of SEQ ID NO: 1231. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 532, the amino acid sequence of SEQ ID NO: 882, and / or the amino acid sequence of SEQ ID NO: 1232. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 533, the amino acid sequence of SEQ ID NO: 883, and / or the amino acid sequence of SEQ ID NO: 1233. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 534, the amino acid sequence of SEQ ID NO: 884, and / or the amino acid sequence of SEQ ID NO: 1234. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 535, the amino acid sequence of SEQ ID NO: 885, and / or the amino acid sequence of SEQ ID NO: 1235. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 536, the amino acid sequence of SEQ ID NO: 886, and / or the amino acid sequence of SEQ ID NO: 1236. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 537, the amino acid sequence of SEQ ID NO: 887, and / or the amino acid sequence of SEQ ID NO: 1237. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 538, the amino acid sequence of SEQ ID NO: 888, and / or the amino acid sequence of SEQ ID NO: 1238. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 539, the amino acid sequence of SEQ ID NO: 889, and / or the amino acid sequence of SEQ ID NO: 1239. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 540, the amino acid sequence of SEQ ID NO: 890, and / or the amino acid sequence of SEQ ID NO: 1240. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 541, the amino acid sequence of SEQ ID NO: 891, and / or the amino acid sequence of SEQ ID NO: 1241. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 542, the amino acid sequence of SEQ ID NO: 892, and / or the amino acid sequence of SEQ ID NO: 1242. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 543, the amino acid sequence of SEQ ID NO: 893, and / or the amino acid sequence of SEQ ID NO: 1243. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 544, the amino acid sequence of SEQ ID NO: 894, and / or the amino acid sequence of SEQ ID NO: 1244. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 545, the amino acid sequence of SEQ ID NO: 895, and / or the amino acid sequence of SEQ ID NO: 1245. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 546, the amino acid sequence of SEQ ID NO: 896, and / or the amino acid sequence of SEQ ID NO: 1246. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 547, the amino acid sequence of SEQ ID NO: 897, and / or the amino acid sequence of SEQ ID NO: 1247. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 548, the amino acid sequence of SEQ ID NO: 898, and / or the amino acid sequence of SEQ ID NO: 1248. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 549, the amino acid sequence of SEQ ID NO: 899, and / or the amino acid sequence of SEQ ID NO: 1249. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 550, the amino acid sequence of SEQ ID NO: 900, and / or the amino acid sequence of SEQ ID NO: 1250. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 551, the amino acid sequence of SEQ ID NO: 901, and / or the amino acid sequence of SEQ ID NO: 1251. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 552, the amino acid sequence of SEQ ID NO: 902, and / or the amino acid sequence of SEQ ID NO: 1252. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 553, the amino acid sequence of SEQ ID NO: 903, and / or the amino acid sequence of SEQ ID NO: 1253. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 554, the amino acid sequence of SEQ ID NO: 904, and / or the amino acid sequence of SEQ ID NO: 1254. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 555, the amino acid sequence of SEQ ID NO: 905, and / or the amino acid sequence of SEQ ID NO: 1255. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 556, the amino acid sequence of SEQ ID NO: 906, and / or the amino acid sequence of SEQ ID NO: 1256. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 557, the amino acid sequence of SEQ ID NO: 907, and / or the amino acid sequence of SEQ ID NO: 1257. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 558, the amino acid sequence of SEQ ID NO: 908, and / or the amino acid sequence of SEQ ID NO: 1258. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 559, the amino acid sequence of SEQ ID NO: 909, and / or the amino acid sequence of SEQ ID NO: 1259. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 560, the amino acid sequence of SEQ ID NO: 910, and / or the amino acid sequence of SEQ ID NO: 1260. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 561, the amino acid sequence of SEQ ID NO: 911, and / or the amino acid sequence of SEQ ID NO: 1261. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 562, the amino acid sequence of SEQ ID NO: 912, and / or the amino acid sequence of SEQ ID NO: 1262. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 563, the amino acid sequence of SEQ ID NO: 913, and / or the amino acid sequence of SEQ ID NO: 1263. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 564, the amino acid sequence of SEQ ID NO: 914, and / or the amino acid sequence of SEQ ID NO: 1264. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 565, the amino acid sequence of SEQ ID NO: 915, and / or the amino acid sequence of SEQ ID NO: 1265. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 566, the amino acid sequence of SEQ ID NO: 916, and / or the amino acid sequence of SEQ ID NO: 1266. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 567, the amino acid sequence of SEQ ID NO: 917, and / or the amino acid sequence of SEQ ID NO: 1267. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 568, the amino acid sequence of SEQ ID NO: 918, and / or the amino acid sequence of SEQ ID NO: 1268. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 569, the amino acid sequence of SEQ ID NO: 919, and / or the amino acid sequence of SEQ ID NO: 1269. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 570, the amino acid sequence of SEQ ID NO: 920, and / or the amino acid sequence of SEQ ID NO: 1270. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 571, the amino acid sequence of SEQ ID NO: 921, and / or the amino acid sequence of SEQ ID NO: 1271. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 572, the amino acid sequence of SEQ ID NO: 922, and / or the amino acid sequence of SEQ ID NO: 1272. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 573, the amino acid sequence of SEQ ID NO: 923, and / or the amino acid sequence of SEQ ID NO: 1273. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 574, the amino acid sequence of SEQ ID NO: 924, and / or the amino acid sequence of SEQ ID NO: 1274. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 575, the amino acid sequence of SEQ ID NO: 925, and / or the amino acid sequence of SEQ ID NO: 1275. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 576, the amino acid sequence of SEQ ID NO: 926, and / or the amino acid sequence of SEQ ID NO: 1276. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 577, the amino acid sequence of SEQ ID NO: 927, and / or the amino acid sequence of SEQ ID NO: 1277. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 578, the amino acid sequence of SEQ ID NO: 928, and / or the amino acid sequence of SEQ ID NO: 1278. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 579, the amino acid sequence of SEQ ID NO: 929, and / or the amino acid sequence of SEQ ID NO: 1279. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 580, the amino acid sequence of SEQ ID NO: 930, and / or the amino acid sequence of SEQ ID NO: 1280. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 581, the amino acid sequence of SEQ ID NO: 931, and / or the amino acid sequence of SEQ ID NO: 1281. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 582, the amino acid sequence of SEQ ID NO: 932, and / or the amino acid sequence of SEQ ID NO: 1282. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 583, the amino acid sequence of SEQ ID NO: 933, and / or the amino acid sequence of SEQ ID NO: 1283. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 584, the amino acid sequence of SEQ ID NO: 934, and / or the amino acid sequence of SEQ ID NO: 1284. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 585, the amino acid sequence of SEQ ID NO: 935, and / or the amino acid sequence of SEQ ID NO: 1285. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 586, the amino acid sequence of SEQ ID NO: 936, and / or the amino acid sequence of SEQ ID NO: 1286. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 587, the amino acid sequence of SEQ ID NO: 937, and / or the amino acid sequence of SEQ ID NO: 1287. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 588, the amino acid sequence of SEQ ID NO: 938, and / or the amino acid sequence of SEQ ID NO: 1288. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 589, the amino acid sequence of SEQ ID NO: 939, and / or the amino acid sequence of SEQ ID NO: 1289. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 590, the amino acid sequence of SEQ ID NO: 940, and / or the amino acid sequence of SEQ ID NO: 1290. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 591, the amino acid sequence of SEQ ID NO: 941, and / or the amino acid sequence of SEQ ID NO: 1291. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 592, the amino acid sequence of SEQ ID NO: 942, and / or the amino acid sequence of SEQ ID NO: 1292. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 593, the amino acid sequence of SEQ ID NO: 943, and / or the amino acid sequence of SEQ ID NO: 1293. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 594, the amino acid sequence of SEQ ID NO: 944, and / or the amino acid sequence of SEQ ID NO: 1294. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 595, the amino acid sequence of SEQ ID NO: 945, and / or the amino acid sequence of SEQ ID NO: 1295. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 596, the amino acid sequence of SEQ ID NO: 946, and / or the amino acid sequence of SEQ ID NO: 1296. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 597, the amino acid sequence of SEQ ID NO: 947, and / or the amino acid sequence of SEQ ID NO: 1297. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 598, the amino acid sequence of SEQ ID NO: 948, and / or the amino acid sequence of SEQ ID NO: 1298. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 599, the amino acid sequence of SEQ ID NO: 949, and / or the amino acid sequence of SEQ ID NO: 1299. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 600, the amino acid sequence of SEQ ID NO: 950, and / or the amino acid sequence of SEQ ID NO: 1300. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 601, the amino acid sequence of SEQ ID NO: 951, and / or the amino acid sequence of SEQ ID NO: 1301. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 602, the amino acid sequence of SEQ ID NO: 952, and / or the amino acid sequence of SEQ ID NO: 1302. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 603, the amino acid sequence of SEQ ID NO: 953, and / or the amino acid sequence of SEQ ID NO: 1303. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 604, the amino acid sequence of SEQ ID NO: 954, and / or the amino acid sequence of SEQ ID NO: 1304. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 605, the amino acid sequence of SEQ ID NO: 955, and / or the amino acid sequence of SEQ ID NO: 1305. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 606, the amino acid sequence of SEQ ID NO: 956, and / or the amino acid sequence of SEQ ID NO: 1306. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 607, the amino acid sequence of SEQ ID NO: 957, and / or the amino acid sequence of SEQ ID NO: 1307. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 608, the amino acid sequence of SEQ ID NO: 958, and / or the amino acid sequence of SEQ ID NO: 1308. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 609, the amino acid sequence of SEQ ID NO: 959, and / or the amino acid sequence of SEQ ID NO: 1309. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 610, the amino acid sequence of SEQ ID NO: 960, and / or the amino acid sequence of SEQ ID NO: 1310. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 611, the amino acid sequence of SEQ ID NO: 961, and / or the amino acid sequence of SEQ ID NO: 1311. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 612, the amino acid sequence of SEQ ID NO: 962, and / or the amino acid sequence of SEQ ID NO: 1312. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 613, the amino acid sequence of SEQ ID NO: 963, and / or the amino acid sequence of SEQ ID NO: 1313. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 614, the amino acid sequence of SEQ ID NO: 964, and / or the amino acid sequence of SEQ ID NO: 1314. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 615, the amino acid sequence of SEQ ID NO: 965, and / or the amino acid sequence of SEQ ID NO: 1315. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 616, the amino acid sequence of SEQ ID NO: 966, and / or the amino acid sequence of SEQ ID NO: 1316. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 617, the amino acid sequence of SEQ ID NO: 967, and / or the amino acid sequence of SEQ ID NO: 1317. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 618, the amino acid sequence of SEQ ID NO: 968, and / or the amino acid sequence of SEQ ID NO: 1318. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 619, the amino acid sequence of SEQ ID NO: 969, and / or the amino acid sequence of SEQ ID NO: 1319. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 620, the amino acid sequence of SEQ ID NO: 970, and / or the amino acid sequence of SEQ ID NO: 1320. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 621, the amino acid sequence of SEQ ID NO: 971, and / or the amino acid sequence of SEQ ID NO: 1321. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 622, the amino acid sequence of SEQ ID NO: 972, and / or the amino acid sequence of SEQ ID NO: 1322. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 623, the amino acid sequence of SEQ ID NO: 973, and / or the amino acid sequence of SEQ ID NO: 1323. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 624, the amino acid sequence of SEQ ID NO: 974, and / or the amino acid sequence of SEQ ID NO: 1324. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 625, the amino acid sequence of SEQ ID NO: 975, and / or the amino acid sequence of SEQ ID NO: 1325. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 626, the amino acid sequence of SEQ ID NO: 976, and / or the amino acid sequence of SEQ ID NO: 1326. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 627, the amino acid sequence of SEQ ID NO: 977, and / or the amino acid sequence of SEQ ID NO: 1327. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 628, the amino acid sequence of SEQ ID NO: 978, and / or the amino acid sequence of SEQ ID NO: 1328. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 629, the amino acid sequence of SEQ ID NO: 979, and / or the amino acid sequence of SEQ ID NO: 1329. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 630, the amino acid sequence of SEQ ID NO: 980, and / or the amino acid sequence of SEQ ID NO: 1330. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 631, the amino acid sequence of SEQ ID NO: 981, and / or the amino acid sequence of SEQ ID NO: 1331. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 632, the amino acid sequence of SEQ ID NO: 982, and / or the amino acid sequence of SEQ ID NO: 1332. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 633, the amino acid sequence of SEQ ID NO: 983, and / or the amino acid sequence of SEQ ID NO: 1333. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 634, the amino acid sequence of SEQ ID NO: 984, and / or the amino acid sequence of SEQ ID NO: 1334. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 635, the amino acid sequence of SEQ ID NO: 985, and / or the amino acid sequence of SEQ ID NO: 1335. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 636, the amino acid sequence of SEQ ID NO: 986, and / or the amino acid sequence of SEQ ID NO: 1336. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 637, the amino acid sequence of SEQ ID NO: 987, and / or the amino acid sequence of SEQ ID NO: 1337. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 638, the amino acid sequence of SEQ ID NO: 988, and / or the amino acid sequence of SEQ ID NO: 1338. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 639, the amino acid sequence of SEQ ID NO: 989, and / or the amino acid sequence of SEQ ID NO: 1339. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 640, the amino acid sequence of SEQ ID NO: 990, and / or the amino acid sequence of SEQ ID NO: 1340. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 641, the amino acid sequence of SEQ ID NO: 991, and / or the amino acid sequence of SEQ ID NO: 1341. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 642, the amino acid sequence of SEQ ID NO: 992, and / or the amino acid sequence of SEQ ID NO: 1342. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 643, the amino acid sequence of SEQ ID NO: 993, and / or the amino acid sequence of SEQ ID NO: 1343. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 644, the amino acid sequence of SEQ ID NO: 994, and / or the amino acid sequence of SEQ ID NO: 1344. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 645, the amino acid sequence of SEQ ID NO: 995, and / or the amino acid sequence of SEQ ID NO: 1345. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 646, the amino acid sequence of SEQ ID NO: 996, and / or the amino acid sequence of SEQ ID NO: 1346. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 647, the amino acid sequence of SEQ ID NO: 997, and / or the amino acid sequence of SEQ ID NO: 1347. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 648, the amino acid sequence of SEQ ID NO: 998, and / or the amino acid sequence of SEQ ID NO: 1348. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 649, the amino acid sequence of SEQ ID NO: 999, and / or the amino acid sequence of SEQ ID NO: 1349. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 650, the amino acid sequence of SEQ ID NO: 1000, and / or the amino acid sequence of SEQ ID NO: 1350. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 651, the amino acid sequence of SEQ ID NO: 1001, and / or the amino acid sequence of SEQ ID NO: 1351. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 652, the amino acid sequence of SEQ ID NO: 1002, and / or the amino acid sequence of SEQ ID NO: 1352. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 653, the amino acid sequence of SEQ ID NO: 1003, and / or the amino acid sequence of SEQ ID NO: 1353. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 654, the amino acid sequence of SEQ ID NO: 1004, and / or the amino acid sequence of SEQ ID NO: 1354. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 655, the amino acid sequence of SEQ ID NO: 1005, and / or the amino acid sequence of SEQ ID NO: 1355. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 656, the amino acid sequence of SEQ ID NO: 1006, and / or the amino acid sequence of SEQ ID NO: 1356. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 657, the amino acid sequence of SEQ ID NO: 1007, and / or the amino acid sequence of SEQ ID NO: 1357. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 658, the amino acid sequence of SEQ ID NO: 1008, and / or the amino acid sequence of SEQ ID NO: 1358. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 659, the amino acid sequence of SEQ ID NO: 1009, and / or the amino acid sequence of SEQ ID NO: 1359. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 660, the amino acid sequence of SEQ ID NO: 1010, and / or the amino acid sequence of SEQ ID NO: 1360. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 661, the amino acid sequence of SEQ ID NO: 1011, and / or the amino acid sequence of SEQ ID NO: 1361. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 662, the amino acid sequence of SEQ ID NO: 1012, and / or the amino acid sequence of SEQ ID NO: 1362. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 663, the amino acid sequence of SEQ ID NO: 1013, and / or the amino acid sequence of SEQ ID NO: 1363. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 664, the amino acid sequence of SEQ ID NO: 1014, and / or the amino acid sequence of SEQ ID NO: 1364. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 665, the amino acid sequence of SEQ ID NO: 1015, and / or the amino acid sequence of SEQ ID NO: 1365. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 666, the amino acid sequence of SEQ ID NO: 1016, and / or the amino acid sequence of SEQ ID NO: 1366. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 667, the amino acid sequence of SEQ ID NO: 1017, and / or the amino acid sequence of SEQ ID NO: 1367. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 668, the amino acid sequence of SEQ ID NO: 1018, and / or the amino acid sequence of SEQ ID NO: 1368. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 669, the amino acid sequence of SEQ ID NO: 1019, and / or the amino acid sequence of SEQ ID NO: 1369. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 670, the amino acid sequence of SEQ ID NO: 1020, and / or the amino acid sequence of SEQ ID NO: 1370. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 671, the amino acid sequence of SEQ ID NO: 1021, and / or the amino acid sequence of SEQ ID NO: 1371. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 672, the amino acid sequence of SEQ ID NO: 1022, and / or the amino acid sequence of SEQ ID NO: 1372. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 673, the amino acid sequence of SEQ ID NO: 1023, and / or the amino acid sequence of SEQ ID NO: 1373. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 674, the amino acid sequence of SEQ ID NO: 1024, and / or the amino acid sequence of SEQ ID NO: 1374. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 675, the amino acid sequence of SEQ ID NO: 1025, and / or the amino acid sequence of SEQ ID NO: 1375. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 676, the amino acid sequence of SEQ ID NO: 1026, and / or the amino acid sequence of SEQ ID NO: 1376. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 677, the amino acid sequence of SEQ ID NO: 1027, and / or the amino acid sequence of SEQ ID NO: 1377. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 678, the amino acid sequence of SEQ ID NO: 1028, and / or the amino acid sequence of SEQ ID NO: 1378. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 679, the amino acid sequence of SEQ ID NO: 1029, and / or the amino acid sequence of SEQ ID NO: 1379. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 680, the amino acid sequence of SEQ ID NO: 1030, and / or the amino acid sequence of SEQ ID NO: 1380. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 681, the amino acid sequence of SEQ ID NO: 1031, and / or the amino acid sequence of SEQ ID NO: 1381. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 682, the amino acid sequence of SEQ ID NO: 1032, and / or the amino acid sequence of SEQ ID NO: 1382. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 683, the amino acid sequence of SEQ ID NO: 1033, and / or the amino acid sequence of SEQ ID NO: 1383. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 684, the amino acid sequence of SEQ ID NO: 1034, and / or the amino acid sequence of SEQ ID NO: 1384. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 685, the amino acid sequence of SEQ ID NO: 1035, and / or the amino acid sequence of SEQ ID NO: 1385. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 686, the amino acid sequence of SEQ ID NO: 1036, and / or the amino acid sequence of SEQ ID NO: 1386. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 687, the amino acid sequence of SEQ ID NO: 1037, and / or the amino acid sequence of SEQ ID NO: 1387. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 688, the amino acid sequence of SEQ ID NO: 1038, and / or the amino acid sequence of SEQ ID NO: 1388. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 689, the amino acid sequence of SEQ ID NO: 1039, and / or the amino acid sequence of SEQ ID NO: 1389. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 690, the amino acid sequence of SEQ ID NO: 1040, and / or the amino acid sequence of SEQ ID NO: 1390. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 691, the amino acid sequence of SEQ ID NO: 1041, and / or the amino acid sequence of SEQ ID NO: 1391. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 692, the amino acid sequence of SEQ ID NO: 1042, and / or the amino acid sequence of SEQ ID NO: 1392. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 693, the amino acid sequence of SEQ ID NO: 1043, and / or the amino acid sequence of SEQ ID NO: 1393. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 694, the amino acid sequence of SEQ ID NO: 1044, and / or the amino acid sequence of SEQ ID NO: 1394. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 695, the amino acid sequence of SEQ ID NO: 1045, and / or the amino acid sequence of SEQ ID NO: 1395. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 696, the amino acid sequence of SEQ ID NO: 1046, and / or the amino acid sequence of SEQ ID NO: 1396. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 697, the amino acid sequence of SEQ ID NO: 1047, and / or the amino acid sequence of SEQ ID NO: 1397. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 698, the amino acid sequence of SEQ ID NO: 1048, and / or the amino acid sequence of SEQ ID NO: 1398. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 699, the amino acid sequence of SEQ ID NO: 1049, and / or the amino acid sequence of SEQ ID NO: 1399. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 700, the amino acid sequence of SEQ ID NO: 1050, and / or the amino acid sequence of SEQ ID NO: 1400.

[0414] In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 1. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 2. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 3. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 4. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 5. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 6. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 11. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 12. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 13. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 15. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 16. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 17. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 18. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 19. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 20. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 21. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 22. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 24. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 25. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 26. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 27. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 28. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 29. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 30. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 31. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 32. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 33. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 34. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 35. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 36. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 37. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 38. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 39. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 40. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 41. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 42. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 43. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 44. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 45. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 46. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 47. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 48. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 49. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 50. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 51. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 52. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 53. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 54. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 55. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 56. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 57. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 58. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 59. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 60. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 61. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 62. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 66. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 67. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 69. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 70. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 71. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 72. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 73. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 74. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 75. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 76. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 77. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 78. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 79. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 80. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 81. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 82. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 83. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 84. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 85. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 86. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 87. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 88. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 89. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 90. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 91. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 92. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 93. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 94. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 95. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 96. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 97. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 98. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 99. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 100. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 101. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 102. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 103. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 104. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 106. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 107. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 108. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 109. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 110. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 111. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 112. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 113. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 114. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 115. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 116. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 117. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 118. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 119. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 120. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 121. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 122. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 123. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 124. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 125. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 126. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 127. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 128. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 129. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 130. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 131. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 132. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 133. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 134. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 135. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 136. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 137. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 138. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 139. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 140. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 141. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 142. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 143. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 144. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 145. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 146. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 147. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 148. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 149. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 150. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 151. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 152. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 153. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 154. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 155. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 156. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 157. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 158. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 159. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 160. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 161. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 162. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 163. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 164. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 165. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 166. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 167. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 168. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 169. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 170. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 171. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 172. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 173. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 174. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 175. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 176. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 177. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 178. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 179. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 180. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 181. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 182. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 183. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 184. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 185. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 186. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 187. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 188. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 189. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 190. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 191. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 192. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 193. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 194. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 195. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 196. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 197. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 198. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 199. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 200. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 201. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 202. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 203. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 204. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 205. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 206. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 207. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 208. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 209. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 210. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 211. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 212. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 213. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 214. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 215. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 216. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 217. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 218. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 219. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 220. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 221. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 222. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 223. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 224. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 225. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 226. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 227. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 228. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 229. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 230. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 231. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 232. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 233. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 234. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 235. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 236. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 237. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 238. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 239. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 240. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 241. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 242. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 243. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 244. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 245. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 246. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 247. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 248. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 249. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 250. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 251. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 252. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 253. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 254. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 255. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 256. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 257. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 258. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 259. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 260. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 261. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 262. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 263. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 264. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 265. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 266. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 267. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 268. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 269. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 270. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 271. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 272. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 273. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 274. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 275. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 276. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 277. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 279. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 280. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 281. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 282. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 283. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 284. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 285. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 286. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 287. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 288. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 289. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 290. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 291. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 292. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 293. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 294. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 295. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 296. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 297. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 298. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 299. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 300. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 302. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 303. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 304. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 305. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 306. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 307. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 308. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 309. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 310. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 312. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 313. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 314. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 315. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 316. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 317. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 318. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 319. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 320. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 321. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 322. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 324. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 325. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 326. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 327. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 328. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 329. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 330. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 331. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 332. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 333. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 334. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 335. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 336. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 337. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 338. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 339. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 340. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 341. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 342. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 343. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 344. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 346. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 347. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 348. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 349. In some embodiments, an antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 350.

[0415] In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 5. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 6. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 7. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 8. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 9. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 10. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 11. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 12. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 13. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 14. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 15. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 16. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 17. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 18. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 19. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 20. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 21. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 22. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 23. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 24. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 25. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 26. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 27. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 28. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 29. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 30. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 31. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 32. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 33. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 37. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 38. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 40. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 41. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 43. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 44. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 45. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 46. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 47. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 48. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 49. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 50. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 51. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 52. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 53. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 54. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 55. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 56. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 57. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 58. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 59. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 60. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 61. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 62. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 63. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 64. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 68. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 70. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 71. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 72. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 73. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 74. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 75. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 76. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 77. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 78. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 79. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 80. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 81. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 82. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 84. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 85. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 86. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 87. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 88. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 94. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 95. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 96. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 97. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 98. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 99. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 100. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 101. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 102. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 103. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 104. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 105. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 106. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 107. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 108. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 109. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 110. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 111. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 112. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 113. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 114. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 115. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 116. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 117. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 118. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 119. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 120. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 121. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 122. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 123. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 124. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 125. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 126. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 127. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 128. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 129. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 130. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 131. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 132. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 133. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 134. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 135. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 136. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 137. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 138. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 139. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 140. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 141. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 142. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 143. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 144. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 145. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 146. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 147. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 148. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 149. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 150. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 151. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 152. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 153. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 154. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 155. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 156. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 157. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 158. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 159. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 160. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 161. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 162. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 163. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 164. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 165. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 166. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 167. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 168. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 169. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 170. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 171. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 172. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 173. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 174. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 175. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 176. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 177. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 178. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 179. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 180. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 181. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 182. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 183. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 184. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 185. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 186. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 187. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 188. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 189. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 190. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 191. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 192. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 193. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 194. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 195. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 196. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 197. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 198. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 199. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 200. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 201. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 202. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 203. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 204. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 205. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 206. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 207. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 208. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 209. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 210. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 211. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 212. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 213. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 214. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 215. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 216. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 217. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 218. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 219. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 220. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 221. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 222. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 223. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 224. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 225. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 226. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 227. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 228. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 229. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 230. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 231. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 232. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 233. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 234. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 235. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 236. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 237. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 238. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 239. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 240. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 241. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 242. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 243. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 244. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 245. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 246. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 247. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 248. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 249. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 250. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 251. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 252. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 253. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 254. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 255. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 256. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 257. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 258. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 259. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 260. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 261. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 262. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 263. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 264. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 265. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 266. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 267. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 268. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 269. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 270. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 271. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 272. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 273. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 274. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 275. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 276. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 277. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 278. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 279. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 280. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 281. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 282. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 283. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 284. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 285. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 286. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 287. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 288. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 289. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 290. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 291. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 292. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 293. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 294. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 295. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 296. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 297. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 298. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 299. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 300. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 301. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 302. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 303. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 304. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 305. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 306. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 307. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 308. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 309. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 310. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 311. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 312. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 313. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 314. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 315. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 316. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 317. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 318. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 319. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 320. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 321. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 322. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 323. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 324. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 325. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 326. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 327. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 328. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 329. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 330. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 331. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 332. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 333. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 334. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 335. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 336. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 337. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 338. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 339. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 340. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 341. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 342. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 343. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 344. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 345. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 346. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 347. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 348. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 349. In some embodiments, an antibody comprises the amino acid sequence of SEQ ID NO: 350.

[0416] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 351; a CDR2 comprising the amino acid sequence of SEQ ID NO: 701; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1051, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 1.

[0417] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 352; a CDR2 comprising the amino acid sequence of SEQ ID NO: 702; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1052, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 2.

[0418] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 353; a CDR2 comprising the amino acid sequence of SEQ ID NO: 703; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1053, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 3.

[0419] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 354; a CDR2 comprising the amino acid sequence of SEQ ID NO: 704; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1054, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 4.

[0420] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 355; a CDR2 comprising the amino acid sequence of SEQ ID NO: 705; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1055, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 5.

[0421] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 356; a CDR2 comprising the amino acid sequence of SEQ ID NO: 706; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1056, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 6. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 357; a CDR2 comprising the amino acid sequence of SEQ ID NO: 707; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1057, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 7.

[0422] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 358; a CDR2 comprising the amino acid sequence of SEQ ID NO: 708; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1058, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 8.

[0423] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 359; a CDR2 comprising the amino acid sequence of SEQ ID NO: 709; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1059, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 9.

[0424] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 360; a CDR2 comprising the amino acid sequence of SEQ ID NO: 710; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1060, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 10.

[0425] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 361; a CDR2 comprising the amino acid sequence of SEQ ID NO: 711; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1061, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 11.

[0426] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 362; a CDR2 comprising the amino acid sequence of SEQ ID NO: 712; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1062, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 12.

[0427] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 363; a CDR2 comprising the amino acid sequence of SEQ ID NO: 713; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1063, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 13.

[0428] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 364; a CDR2 comprising the amino acid sequence of SEQ ID NO: 714; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1064, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 14.

[0429] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 365; a CDR2 comprising the amino acid sequence of SEQ ID NO: 715; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1065, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 15.

[0430] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 366; a CDR2 comprising the amino acid sequence of SEQ ID NO: 716; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1066, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 16.

[0431] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 367; a CDR2 comprising the amino acid sequence of SEQ ID NO: 717; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1067, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 17. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 17.

[0432] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 368; a CDR2 comprising the amino acid sequence of SEQ ID NO: 718; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1068, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 18.

[0433] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 369; a CDR2 comprising the amino acid sequence of SEQ ID NO: 719; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1069, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 19. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 19.

[0434] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 370; a CDR2 comprising the amino acid sequence of SEQ ID NO: 720; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1070, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 20. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 371; a CDR2 comprising the amino acid sequence of SEQ ID NO: 721; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1071, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 21. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 21.

[0435] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 372; a CDR2 comprising the amino acid sequence of SEQ ID NO: 722; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1072, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 22.

[0436] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 373; a CDR2 comprising the amino acid sequence of SEQ ID NO: 723; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1073, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 23.

[0437] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 374; a CDR2 comprising the amino acid sequence of SEQ ID NO: 724; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1074, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 24. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 24.

[0438] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 375; a CDR2 comprising the amino acid sequence of SEQ ID NO: 725; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1075, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 25. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 25.

[0439] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 376; a CDR2 comprising the amino acid sequence of SEQ ID NO: 726; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1076, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 26. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 26.

[0440] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 377; a CDR2 comprising the amino acid sequence of SEQ ID NO: 727; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1077, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 27. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 27.

[0441] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 378; a CDR2 comprising the amino acid sequence of SEQ ID NO: 728; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1078, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 28. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 28.

[0442] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 379; a CDR2 comprising the amino acid sequence of SEQ ID NO: 729; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1079, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 29. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 29.

[0443] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 380; a CDR2 comprising the amino acid sequence of SEQ ID NO: 730; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1080, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 30.

[0444] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 381; a CDR2 comprising the amino acid sequence of SEQ ID NO: 731; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1081, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 31.

[0445] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 382; a CDR2 comprising the amino acid sequence of SEQ ID NO: 732; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1082, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 32.

[0446] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 383; a CDR2 comprising the amino acid sequence of SEQ ID NO: 733; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1083, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 33. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 33.

[0447] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 384; a CDR2 comprising the amino acid sequence of SEQ ID NO: 734; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1084, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 34. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 34. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 385; a CDR2 comprising the amino acid sequence of SEQ ID NO: 735; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1085, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 35.

[0448] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 386; a CDR2 comprising the amino acid sequence of SEQ ID NO: 736; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1086, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 36. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 36.

[0449] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 387; a CDR2 comprising the amino acid sequence of SEQ ID NO: 737; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1087, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 37.

[0450] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 388; a CDR2 comprising the amino acid sequence of SEQ ID NO: 738; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1088, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 38. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 38.

[0451] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 389; a CDR2 comprising the amino acid sequence of SEQ ID NO: 739; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1089, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 39. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 39.

[0452] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 390; a CDR2 comprising the amino acid sequence of SEQ ID NO: 740; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1090, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 40.

[0453] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 391; a CDR2 comprising the amino acid sequence of SEQ ID NO: 741; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1091, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 41. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 41.

[0454] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 392; a CDR2 comprising the amino acid sequence of SEQ ID NO: 742; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1092, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 42. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 42.

[0455] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 393; a CDR2 comprising the amino acid sequence of SEQ ID NO: 743; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1093, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 43. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 43.

[0456] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 394; a CDR2 comprising the amino acid sequence of SEQ ID NO: 744; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1094, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 44.

[0457] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 395; a CDR2 comprising the amino acid sequence of SEQ ID NO: 745; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1095, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 45. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 45.

[0458] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 396; a CDR2 comprising the amino acid sequence of SEQ ID NO: 746; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1096, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 46. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 46.

[0459] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 397; a CDR2 comprising the amino acid sequence of SEQ ID NO: 747; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1097, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 47. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 47.

[0460] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 398; a CDR2 comprising the amino acid sequence of SEQ ID NO: 748; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1098, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 48. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 48. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 399; a CDR2 comprising the amino acid sequence of SEQ ID NO: 749; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1099, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 49. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 49.

[0461] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 400; a CDR2 comprising the amino acid sequence of SEQ ID NO: 750; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1100, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 50.

[0462] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 401; a CDR2 comprising the amino acid sequence of SEQ ID NO: 751; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1101, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 51.

[0463] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 402; a CDR2 comprising the amino acid sequence of SEQ ID NO: 752; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1102, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 52.

[0464] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 403; a CDR2 comprising the amino acid sequence of SEQ ID NO: 753; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1103, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 53.

[0465] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 404; a CDR2 comprising the amino acid sequence of SEQ ID NO: 754; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1104, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 54.

[0466] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 405; a CDR2 comprising the amino acid sequence of SEQ ID NO: 755; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1105, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 55.

[0467] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 406; a CDR2 comprising the amino acid sequence of SEQ ID NO: 756; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1106, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 56. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 56.

[0468] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 407; a CDR2 comprising the amino acid sequence of SEQ ID NO: 757; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1107, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 57. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 57.

[0469] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 408; a CDR2 comprising the amino acid sequence of SEQ ID NO: 758; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1108, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 58.

[0470] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 409; a CDR2 comprising the amino acid sequence of SEQ ID NO: 759; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1109, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 59.

[0471] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 410; a CDR2 comprising the amino acid sequence of SEQ ID NO: 760; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1110, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 60. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 60.

[0472] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 411; a CDR2 comprising the amino acid sequence of SEQ ID NO: 761; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1111, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 61. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 61.

[0473] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 412; a CDR2 comprising the amino acid sequence of SEQ ID NO: 762; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1112, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 62. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 62. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 413; a CDR2 comprising the amino acid sequence of SEQ ID NO: 763; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1113, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 63.

[0474] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 414; a CDR2 comprising the amino acid sequence of SEQ ID NO: 764; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1114, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 64.

[0475] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 415; a CDR2 comprising the amino acid sequence of SEQ ID NO: 765; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1115, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 65.

[0476] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 416; a CDR2 comprising the amino acid sequence of SEQ ID NO: 766; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1116, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 66. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 66.

[0477] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 417; a CDR2 comprising the amino acid sequence of SEQ ID NO: 767; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1117, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 67.

[0478] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 418; a CDR2 comprising the amino acid sequence of SEQ ID NO: 768; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1118, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 68.

[0479] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 419; a CDR2 comprising the amino acid sequence of SEQ ID NO: 769; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1119, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 69. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 69.

[0480] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 420; a CDR2 comprising the amino acid sequence of SEQ ID NO: 770; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1120, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 70. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 70.

[0481] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 421; a CDR2 comprising the amino acid sequence of SEQ ID NO: 771; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1121, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 71. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 71.

[0482] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 422; a CDR2 comprising the amino acid sequence of SEQ ID NO: 772; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1122, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 72.

[0483] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 423; a CDR2 comprising the amino acid sequence of SEQ ID NO: 773; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1123, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 73. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 73.

[0484] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 424; a CDR2 comprising the amino acid sequence of SEQ ID NO: 774; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1124, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 74.

[0485] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 425; a CDR2 comprising the amino acid sequence of SEQ ID NO: 775; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1125, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 75.

[0486] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 426; a CDR2 comprising the amino acid sequence of SEQ ID NO: 776; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1126, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 76. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 76. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 427; a CDR2 comprising the amino acid sequence of SEQ ID NO: 777; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1127, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 77. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 77.

[0487] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 428; a CDR2 comprising the amino acid sequence of SEQ ID NO: 778; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1128, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 78. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 78.

[0488] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 429; a CDR2 comprising the amino acid sequence of SEQ ID NO: 779; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1129, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 79.

[0489] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 430; a CDR2 comprising the amino acid sequence of SEQ ID NO: 780; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1130, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 80. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 80.

[0490] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 431; a CDR2 comprising the amino acid sequence of SEQ ID NO: 781; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1131, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 81. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 81.

[0491] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 432; a CDR2 comprising the amino acid sequence of SEQ ID NO: 782; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1132, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 82. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 82.

[0492] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 433; a CDR2 comprising the amino acid sequence of SEQ ID NO: 783; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1133, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 83. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 83.

[0493] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 434; a CDR2 comprising the amino acid sequence of SEQ ID NO: 784; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1134, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 84. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 84.

[0494] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 435; a CDR2 comprising the amino acid sequence of SEQ ID NO: 785; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1135, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 85. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 85.

[0495] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 436; a CDR2 comprising the amino acid sequence of SEQ ID NO: 786; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1136, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 86. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 86.

[0496] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 437; a CDR2 comprising the amino acid sequence of SEQ ID NO: 787; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1137, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 87. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 87.

[0497] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 438; a CDR2 comprising the amino acid sequence of SEQ ID NO: 788; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1138, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 88.

[0498] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 439; a CDR2 comprising the amino acid sequence of SEQ ID NO: 789; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1139, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 89. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 89.

[0499] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 440; a CDR2 comprising the amino acid sequence of SEQ ID NO: 790; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1140, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 90. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 90. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 441; a CDR2 comprising the amino acid sequence of SEQ ID NO: 791; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1141, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 91. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 91.

[0500] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 442; a CDR2 comprising the amino acid sequence of SEQ ID NO: 792; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1142, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 92. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 92.

[0501] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 443; a CDR2 comprising the amino acid sequence of SEQ ID NO: 793; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1143, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 93. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 93.

[0502] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 444; a CDR2 comprising the amino acid sequence of SEQ ID NO: 794; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1144, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 94. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 94.

[0503] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 445; a CDR2 comprising the amino acid sequence of SEQ ID NO: 795; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1145, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 95.

[0504] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 446; a CDR2 comprising the amino acid sequence of SEQ ID NO: 796; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1146, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 96. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 96.

[0505] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 447; a CDR2 comprising the amino acid sequence of SEQ ID NO: 797; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1147, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 97. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 97.

[0506] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 448; a CDR2 comprising the amino acid sequence of SEQ ID NO: 798; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1148, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 98. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 98.

[0507] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 449; a CDR2 comprising the amino acid sequence of SEQ ID NO: 799; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1149, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 99. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 99.

[0508] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 450; a CDR2 comprising the amino acid sequence of SEQ ID NO: 800; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1150, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 100.

[0509] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 451; a CDR2 comprising the amino acid sequence of SEQ ID NO: 801; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1151, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 101. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 101.

[0510] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 452; a CDR2 comprising the amino acid sequence of SEQ ID NO: 802; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1152, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 102.

[0511] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 453; a CDR2 comprising the amino acid sequence of SEQ ID NO: 803; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1153, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 103. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 103.

[0512] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 454; a CDR2 comprising the amino acid sequence of SEQ ID NO: 804; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1154, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 104. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 104. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 455; a CDR2 comprising the amino acid sequence of SEQ ID NO: 805; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1155, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 105.

[0513] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 456; a CDR2 comprising the amino acid sequence of SEQ ID NO: 806; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1156, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 106. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 106.

[0514] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 457; a CDR2 comprising the amino acid sequence of SEQ ID NO: 807; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1157, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 107.

[0515] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 458; a CDR2 comprising the amino acid sequence of SEQ ID NO: 808; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1158, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 108. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 108.

[0516] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 459; a CDR2 comprising the amino acid sequence of SEQ ID NO: 809; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1159, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 109.

[0517] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 460; a CDR2 comprising the amino acid sequence of SEQ ID NO: 810; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1160, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 110. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 110.

[0518] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 461; a CDR2 comprising the amino acid sequence of SEQ ID NO: 811; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1161, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 111. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 111.

[0519] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 462; a CDR2 comprising the amino acid sequence of SEQ ID NO: 812; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1162, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 112. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 112.

[0520] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 463; a CDR2 comprising the amino acid sequence of SEQ ID NO: 813; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1163, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 113.

[0521] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 464; a CDR2 comprising the amino acid sequence of SEQ ID NO: 814; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1164, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 114.

[0522] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 465; a CDR2 comprising the amino acid sequence of SEQ ID NO: 815; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1165, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 115. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 115.

[0523] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 466; a CDR2 comprising the amino acid sequence of SEQ ID NO: 816; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1166, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 116. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 116.

[0524] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 467; a CDR2 comprising the amino acid sequence of SEQ ID NO: 817; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1167, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 117. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 117.

[0525] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 468; a CDR2 comprising the amino acid sequence of SEQ ID NO: 818; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1168, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 118. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 118. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 469; a CDR2 comprising the amino acid sequence of SEQ ID NO: 819; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1169, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 119. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 119.

[0526] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 470; a CDR2 comprising the amino acid sequence of SEQ ID NO: 820; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1170, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 120. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 120.

[0527] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 471; a CDR2 comprising the amino acid sequence of SEQ ID NO: 821; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1171, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 121.

[0528] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 472; a CDR2 comprising the amino acid sequence of SEQ ID NO: 822; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1172, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 122. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 122.

[0529] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 473; a CDR2 comprising the amino acid sequence of SEQ ID NO: 823; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1173, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 123.

[0530] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 474; a CDR2 comprising the amino acid sequence of SEQ ID NO: 824; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1174, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 124.

[0531] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 475; a CDR2 comprising the amino acid sequence of SEQ ID NO: 825; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1175, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 125. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 125.

[0532] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 476; a CDR2 comprising the amino acid sequence of SEQ ID NO: 826; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1176, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 126. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 126.

[0533] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 477; a CDR2 comprising the amino acid sequence of SEQ ID NO: 827; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1177, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 127. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 127.

[0534] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 478; a CDR2 comprising the amino acid sequence of SEQ ID NO: 828; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1178, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 128.

[0535] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 479; a CDR2 comprising the amino acid sequence of SEQ ID NO: 829; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1179, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 129. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 129.

[0536] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 480; a CDR2 comprising the amino acid sequence of SEQ ID NO: 830; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1180, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 130. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 130.

[0537] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 481; a CDR2 comprising the amino acid sequence of SEQ ID NO: 831; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1181, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 131. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 131.

[0538] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 482; a CDR2 comprising the amino acid sequence of SEQ ID NO: 832; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1182, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 132. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 132. In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 483; a CDR2 comprising the amino acid sequence of SEQ ID NO: 833; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1183, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 133. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 133.

[0539] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 484; a CDR2 comprising the amino acid sequence of SEQ ID NO: 834; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1184, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 134.

[0540] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 485; a CDR2 comprising the amino acid sequence of SEQ ID NO: 835; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1185, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 135.

[0541] In some aspects, an antibody comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 486; a CDR2 comprising the amino acid sequence of SEQ ID NO: 836; and / or a CDR3 comprising the amino acid sequence of SEQ ID NO: 1186, wherein the antibody binds to 5T4. In some embodiments, the antibody comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 136. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO: 136.

[0542] In so...

Claims

What is claimed is:CLAIMS1. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of any one of SEQ ID NOs: 351-700; a complementary determining region 2 (CDR2) comprising the amino acid sequence of any one of SEQ ID NOs: 701-1050; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of any one of SEQ ID NOs: 1051-1400, wherein the antibody binds to 5T4.

2. The antibody of claim 1, wherein the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 1-350, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of any one of SEQ ID NOs: 1-350.

3. The antibody of any one of the preceding claims, wherein the equilibrium dissociation constant (KD) of binding of the antibody to the 5T4 is in a range from 10'9M to 10'11M.

4. The antibody of any one of the preceding claims, wherein the equilibrium dissociation constant (KD) of binding of the antibody to the 5T4 is in a range from 1 nM to 0.01 nM.

5. The antibody of any one of the preceding claims, wherein the antibody selectively binds to human 5T4 relative to a non-human 5T4.

6. The antibody of any one of the preceding claims, wherein the antibody binds to human 5T4, mouse 5T4, cynomolgus monkey 5T4, or any combination thereof.

7. The antibody of any one of the preceding claims, wherein the antibody is a single chain antibody.

8. The antibody of claim 7, wherein the single chain antibody is a heavy-chain variable domain (VHH) antibody or a single-chain variable fragment (scFv) antibody.

9. The antibody of any one of the preceding claims, wherein the antibody is a humanized antibody.

10. The antibody of any one of the preceding claims, wherein the antibody is a chimeric antibody.

11. A cell comprising the antibody of any one of the preceding claims, optionally wherein the cell is a cancer cell.

12. A conjugate comprising the antibody of any one of the preceding claims.

13. The conjugate of claim 12 further comprising a radionuclide.

14. A pharmaceutical composition comprising the antibody of any one of claims 1-10, or the conjugate of claim 12 or 13, and a pharmaceutically acceptable excipient.

15. A method comprising administering to a subject the antibody of any one of claims 1-10, the conjugate of claim 12 or 13, or the pharmaceutical composition of claim 14.

16. A nucleic acid or set of nucleic acids encoding the antibody of any one of claims 1-10.

17. A vector or set of vectors comprising one or more nucleic acid encoding the antibody of any one of claims 1-10.

18. A method of producing the antibody of any one of claims 1-10, the method comprising culturing the cell of claim 14 in cell culture and obtaining the antibody from the cell or cell culture.

19. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 593; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 943; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1293, wherein the antibody binds to 5T4.

20. The antibody of claim 19, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 243, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 243.

21. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 421; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 771; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1121, wherein the antibody binds to 5T4.

22. The antibody of claim 21, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 71.

23. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 658; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 1008; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1358,wherein the antibody binds to 5T4.

24. The antibody of claim 23, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 308, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 308.

25. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 632; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 982; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1332, wherein the antibody binds to 5T4.

26. The antibody of claim 25, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 282, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 282.

27. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 483; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 833; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1183, wherein the antibody binds to 5T4.

28. The antibody of claim 27, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 133, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 133.

29. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 445; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 795; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1145, wherein the antibody binds to 5T4.

30. The antibody of claim 29, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 95, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 95.

31. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 408; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 758; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1108, wherein the antibody binds to 5T4.

32. The antibody of claim 31, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 58, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 58.

33. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 381; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 731; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1081,wherein the antibody binds to 5T4.

34. The antibody of claim 33, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 31, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 31.

35. An antibody comprising: a complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 623; a complementary determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 973; and / or a complementary determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 1323, wherein the antibody binds to 5T4.

36. The antibody of claim 35, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 273, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% identity to the amino acid sequence of SEQ ID NO: 273.

37. The antibody of any one of claims 19-36, wherein the equilibrium dissociation constant (KD) of binding of the antibody to the 5T4 is in a range from 10'9M to 101M.

38. The antibody of any one of claims 19-37, wherein the equilibrium dissociation constant (KD) of binding of the antibody to the 5T4 is in a range from 1 nM to 0.01 nM.

39. The antibody of any one of claims 19-38, wherein the antibody selectively binds to human 5T4 relative to a non-human 5T4.

40. The antibody of any one of claims 19-39, wherein the antibody binds to human 5T4, mouse 5T4, cynomolgus monkey 5T4, or any combination thereof.

41. The antibody of any one of claims 19-40, wherein the antibody is a single chain antibody.

42. The antibody of claim 41, wherein the single chain antibody is a heavy-chain variable domain (VHH) antibody or a single-chain variable fragment (scFv) antibody.

43. The antibody of any one of claims 19-42, wherein the antibody is a humanized antibody.

44. The antibody of any one of claims 19-43, wherein the antibody is a chimeric antibody.

45. A cell comprising the antibody of any one of the preceding claims, optionally wherein the cell is a cancer cell.

46. A conjugate comprising the antibody of any one of claims 19-44.

47. The conjugate of claim 46 further comprising a radionuclide.

48. A pharmaceutical composition comprising the antibody of any one of claims 19-44, or the conjugate of claim 46 or 47, and a pharmaceutically acceptable excipient.

49. A method comprising administering to a subject the antibody of any one of claims 19-44, the conjugate of claim 46 or 47, or the pharmaceutical composition of claim 48.

50. A nucleic acid or set of nucleic acids encoding the antibody of any one of claims 19-44.

51. A vector or set of vectors comprising one or more nucleic acid encoding the antibody of any one of claims 19-44.

52. A method of producing the antibody of any one of claims 19-44, the method comprising culturing the cell of claim 47 in cell culture and obtaining the antibody from the cell or cell culture.

Images